Diovan Related Published Studies
Well-designed clinical trials related to Diovan (Valsartan)
Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. [2008.10]
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). [2008.09.16]
Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. [2008.08]
Randomized, Double-blinded Trial Evaluation of Valsartan/Hydrochlorothiazide Combination Therapy in Mild to Moderate Essential Hypertension in North-east China. [2008.07]
Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. [2008.07]
A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. [2008.07]
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. [2008.06]
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.06]
Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). [2008.06]
[Valsartan improves symptoms and quality of life in patients with chronic heart failure] [2008.04.10]
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. [2008.04]
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial. [2008.03]
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.01.24]
Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results. [2008.01]
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. [2008]
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. [2007.09]
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. [2007.09]
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. [2007.09]
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. [2007.08.28]
[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients] [2007.08]
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. [2007.07.21]
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. [2007.07.15]
Effect of Fluvastatin and Valsartan, Alone and in Combination, on Postprandial Vascular Inflammation and Fibrinolytic Activity in Patients With Essential Hypertension. [2007.07]
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. [2007.05]
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. [2007.04]
Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. [2007.03]
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. [2007.03]
Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. [2007.03]
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. [2007.03]
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. [2007.03]
Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. [2007.01]
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. [2007.01]
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. [2007]
[Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease.] [2007]
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. [2006.12]
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. [2006.12]
Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. [2006.10]
Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. [2006.10]
Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. [2006.10]
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. [2006.09]
Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. [2006.09]
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. [2006.09]
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. [2006.08]
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. [2006.07]
Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. [2006.07]
Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. [2006.07]
Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial. [2006.06]
Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design. [2006.05]
Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. [2006.05]
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. [2006.05]
Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. [2006.04]
The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism. [2006.03]
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). [2006.02.21]
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. [2006.01]
Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. [2005.11]
Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. [2005.10]
Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. [2005.10]
Treatment of non-dipper hypertension with bedtime administration of valsartan. [2005.10]
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. [2005.09]
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). [2005.08]
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. [2005.08]
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. [2005.07]
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. [2005.07]
A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population. [2005.06]
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. [2005.05]
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. [2005.05]
Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. [2005.05]
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. [2005.04]
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. [2005.03]
Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril. [2005.03]
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. [2005.03]
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). [2005.02.15]
Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. [2005.01]
Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. [2005]
The effects of valsartan on lipid profile in normotensive type 2 diabetic patients. [2005]
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. [2005]
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). [2004.12]
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. [2004.12]
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. [2004.12]
Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. [2004.11]
Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. [2004.08]
Sustained antihypertensive activity of telmisartan compared with valsartan. [2004.08]
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. [2004.07]
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). [2004.07]
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. [2004.06.19]
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. [2004.06.02]
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. [2004.06.02]
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [2004.06]
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. [2004.06]
Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. [2004.05]
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. [2004.04]
Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). [2004.04]
Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. [2004.04]
Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. [2004.03]
The benefits of valsartan in the treatment of heart failure: results from Val-HeFT. [2004.02]
Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. [2004.02]
Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. [2004.02]
Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. [2004.01]
Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. [2004.01]
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. [2003.12]
|
